Central Trust CO Neurocrine Biosciences Inc Transaction History
Central Trust CO
- $4 Billion
- Q4 2024
A detailed history of Central Trust CO transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Central Trust CO holds 86 shares of NBIX stock, worth $13,003. This represents 0.0% of its overall portfolio holdings.
Number of Shares
86
Previous 76
13.16%
Holding current value
$13,003
Previous $8,000
37.5%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding NBIX
# of Institutions
642Shares Held
94.2MCall Options Held
632KPut Options Held
621K-
Black Rock Inc. New York, NY14.2MShares$2.15 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10MShares$1.51 Billion0.02% of portfolio
-
State Street Corp Boston, MA5.15MShares$778 Million0.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.57MShares$389 Million0.47% of portfolio
-
Bellevue Group Ag Kuesnacht, V81.86MShares$282 Million3.62% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $14.5B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...